ar 100

Iclaprim (AR-100) is a novel specific bacterial Dihydrofolate inhibitor. It can inhibit the growth of S. aureus (MIC90: 0.06 μg/mL).

AR-L 100 BS is a bioactive chemical with cardiovascular effects and blood pressure.

Edg-2 receptor inhibitor 1 (SAR-100842) is an Edg-2 receptor inhibitor extracted (IC50: <0.1 μM).

DSPE-pSar100 (DSPE-Polysarcosine100) is a lipid derivative of polysarcosine. It serves as a hydrophilic substitute for PEG and is utilized in drug delivery research.

Azide-pSar100 (Azide-Polysarcosine100) is a pSar-lipid derivative. It serves as a hydrophilic alternative to PEG and is applicable in drug delivery research.

BMY 7378 (free base) is a selective antagonist for the α1D adrenergic receptor (α1D-AR). It exhibits a membrane-binding affinity for cloned rat α1D-AR (Ki=2 nM) that is over 100 times stronger than its affinity for cloned rat α1A-AR (Ki=800 nM) or hamster α1B-AR (Ki=600 nM). Additionally, BMY 7378 (free base) acts as a partial agonist at the 5-HT1A receptor.

PROTACAR Degrader-10 is a protein degrader targeting androgen receptors (AR) with a DC50 value of ≤100 nM, and can be used in prostate cancer research.

BMY 7378 dihydrochloride (BMY7378 HCl) , α1D-adrenergic receptor antagonist, is a weak partial agonist/antagonist of 5-HT1A receptor.

YXG-158 (Compound 23-h), an orally active androgen receptor (AR) degrader and cytochrome P450 17A1 (CYP17A1) inhibitor, exhibits AR degradation with a DC50 of 1.28 μM and CYP17A1 inhibition with an IC50 of 100 nM. It is under investigation for potential use in research on enzalutamide-resistant prostate cancer [1].